Staff Profile
Emeritus Professor David Bates
Emeritus Professor
- Email: david.bates@ncl.ac.uk
- Telephone: +44 (0) 191 282 4949
- Fax: +44 (0) 191 261 0881
- Address: Department of Neurology
Ward 11
The Royal Victoria Infirmary
Queen Victoria Road
Newcastle upon Tyne
NE1 4LP
David Bates is Emeritus Professor of Clinical Neurology at Newcastle University, UK. He served as Chairman of the Joint Colleges Working Party on the Vegetative State and Criteria for Brain Stem Death, London, UK, and Chairman of the Consensus Conference on the Epilepsies for the Royal College of Physicians, Edinburgh, UK. He is past Chairman of the International MS Forum, past Chairman of the Medical Research Advisory Committee of the MS Society of Great Britain and Northern Ireland, and Former Editor of the International MS Journal.
His research interests are in vascular disease, coma and the unconscious patient, and in MS. His current research is predominantly in clinical trials of novel therapy in MS and in the role of mitochondria in protecting and repairing axons in the more chronic phases of the disease.
Professor Bates studied medicine at Downing College, Cambridge University, UK, and at Middlesex Hospital, London, UK, before training in neurology at the University of Newcastle upon Tyne and, as Harkness Fellow, at the Mayo Clinic, Rochester, Minnesota, USA. He has published more than 200 peer-reviewed papers, edited three textbooks and contributed chapters to more than 35 books.
Area of expertise: Multiple Sclerosis and Coma
- Tolley CL, Slight SP, Husband AK, Watson N, Bates DW. Improving medication-related clinical decision support. American Journal of Health-System Pharmacy 2018, 75(4), 239-246.
- Nanji KC, Seger DL, Slight SP, Amato M, Beeler P, Her Q, Dalleur O, Eguale T, Wong A, Silvers E, Swerdloff M, Maniam N, Fiskio J, Dykes P, Bates DW. Medication-related clinical decision support alert overrides in inpatients. Journal of the American Medical Informatics Association 2018, 25(5), 476-481.
- Bates D. Lord Walton of Detchant Obituary. Journal of the Neurological Sciences 2016, 367, 34-35.
- Walker A, Watson C, Alexopoulos ST, Deniz B, Arnold R, Bates D. A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy. Current Medical Research and Opinion 2014, 30(4), 629-635.
- Carroll WM, Saida T, Kim HJ, Kira J, Kermode AG, Tsai CP, Fujihara K, Kusunoki S, Tanaka M, Kim KK, Bates D. A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica). Multiple Sclerosis Journal 2013, 19(10), 1371-1380.
- Bates D, Burks J, Globe D, Signori M, Hudgens S, Denys P, MacDiarmid S, Nitti V, Odderson I, Ross AP, Chancellor M. Development of a short form and scoring algorithm from the validated actionable bladder symptom screening tool. BMC Neurology 2013, 13, 78.
- Havrdova E, Bates D, Galetta S, Giovannoni G, Hutchinson M, Lublin F, O'Connor P, Pellegrini F, Phillips J, Polman C, Wiendl H, Belachew S, Patel R, Pace A. Effects of natalizumab treatment on freedom from disease activity by baseline characteristics in AFFIRM. In: 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) and the 18th Annual Conference of Rehabilitation in MS (RIMS). 2013, Copenhagen, Denmark: Sage Publications.
- Fredrikson S, McLeod E, Henry N, Pitcher A, Cuche M, Fajutrao L, Perard R, Bates D, Chan A. A cost-effectiveness analysis of subcutaneous interferon-beta-1a 44mcg three times a week versus no treatment for patients with a single demyelinating event in Sweden. 2012, Sage.
- Walker AR, Deniz B, Alexopoulos ST, Arnold R, Bates D. A Risk-Benefit Analysis of Natalizumab Across PML Risk Sub-Groups in Patients with Relapsing-Remitting Multiple Sclerosis. In: ISPOR 17th Annual International Meeting. 2012, Washington, DC, USA: Elsevier.
- Alexopoulos ST, Deniz B, Walker AR, Arnold R, Bates D. Economic Evaluation of Natalizumab Versus Fingolimod for the Treatment of Replapsing-Remitting Multiple Sclerosis in Sweden. In: ISPOR 17th Annual International Meeting. 2012, Washington, DC, USA: Elsevier.
- Bates D, Bartholome E. Treatment effect of natalizumab on relapse outcomes in multiple sclerosis patients despite ongoing MRI activity. Journal of Neurology, Neurosurgery and Psychiatry 2012, 83(1), 55-60.
- Denys P, Bates D, Burks J, Chancellor M, Signori M, Globe D, Fitz-Randolph M, Hudgens S. Methodology and validation of urinary incontinence in multiple sclerosis screening tool. In: European Journal of Neurology: 15th Congress of the European Federation of Neurological Societies (EFNS). 2011, Budapest, Hungary: Wiley-Blackwell Publishing Ltd.
- Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. LANCET NEUROLOGY 2009, 8(3), 254-260.
- Kieseier BC, Putzki N, Bates D, Hutchinson M, Pace A, Hyde R. Natalizumab improves quality-of-life outcomes in patients with highly active multiple sclerosis. In: JOURNAL OF NEUROLOGY. 2009, TIERGARTENSTRASSE 17, 69121 HEIDELBERG, GERMANY: DR DIETRICH STEINKOPFF VERLAG.
- Kieseier BC, Putzki N, Bates D, Hutchinson M, Pace A, Hyde R. The effect of natalizumab therapy on quality of life outcomes in multiple sclerosis patients with non-highly active disease. In: MULTIPLE SCLEROSIS. 2009, 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.
- Gani R, Giovannoni G, Bates D, Kemball B, Hughes S, Kerrigan J. Cost-effectiveness analyses of natalizumab (Tysabri (R)) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. PHARMACOECONOMICS 2008, 26(7), 617-627.
- Bates D, Bartholome E, Pace A, Hyde R, Hotermans C. Effect of natalizumab on relapses in patients with relapsing multiple sclerosis who experience MRI activity during treatment. In: MULTIPLE SCLEROSIS. 2008, 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.
- Havrdova E, Bates D, Galetta SL, Giovannoni G, Lublin F, O'Connor P, Phillips JT, Polman C, Stefoski D, Pace A, Hyde R, Kim R, Panzara M. Natalizumab increases the proportion of disease-free patients in relapsing multiple sclerosis. In: MULTIPLE SCLEROSIS JOURNAL. 2008, 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.
- Bates D, Comi G. The way forward to treatment optimisation in multiple sclerosis: Introduction. Journal of Neurology, Supplement 2004, 251(s5), V/2.
- Powell H, Archibald K, Mountford R, Lynch SA, Bates D, Curtis A. A deletion within the frataxin gene, combined with a GAA expansion mutation causes atypical Friedreich ataxia. In: Journal of Medical Genetics: British Human Genetics Conference. 2003, York, UK: BMJ Group.
- Dalton C, Barker G, MacManus D, Miszkiel K, Bates D, Blumhardt L, Hawkins C, Palace J, Sharief M, Swingler R, Young C, Miller D, Int Natalizumab MS Trial Grp. The effectiveness of Natalizumab on MRI outcome measures in patients with relapsing multiple sclerosis. In: Journal of Neurology, Neurosurgery and Psychiatry: Joint Congress of the Association of British Neurologists/British Neuropsychiatry Association. 2003, London, UK: BMJ Group.
- Curtis ARJ, Fey C, Morris CM, Bindoff LA, Ince PG, Chinnery PF, Coulthard A, Jackson MJ, Jackson AP, McHale DP, Hay D, Barker WA, Markham AF, Bates D, Curtis A, Burn J. Mutation in ferritin light chain causes dominant adult onset neurodegeneration. Nature Genetics 2001, 28(4), 350-354.
- Bates D. The prognosis of medical coma. Journal of Neurology, Neurosurgery and Psychiatry 2001, 71(s1), 20-23.
- Burn J, Curtis AR, Bindoff L, Ince P, Coulthard A, Jackson A, Jackson M, Fey C, Hay D, Shepherd D, Bates D, Curtis A. A novel autosomal dominant basal ganglia degeneration with cavitation on 19q can mimic Parkinson's disease and Huntington's disease. American Journal of Human Genetics 2000, 67(4), 371-371.
- Nodder D, Chappell B, Bates D, Freeman J, Hatch J, Keen J, Thomas S, Young C. Multiple sclerosis: care needs for 2000 and beyond. Journal of the Royal Society of Medicine 2000, 93(5), 219-224.
- Bates D. Advances in diagnosis. In: KEY ADVANCES IN THE EFFECTIVE MANAGEMENT OF MULTIPLE SCLEROSIS. 1999, 1 WIMPOLE STREET, LONDON W1M 8AE, ENGLAND: ROYAL SOC MEDICINE PRESS LTD.
- Coulthard A, Hall K, English PT, Ince PG, Burn DJ, Bates D. Quantitative analysis of MRI signal intensity in new variant Creutzfeldt-Jakob disease. British Journal of Radiology 1999, 72(860), 742-748.
- SPRIGGS DA, BURN DJ, FRENCH J, CARTLIDGE NEF, BATES D. IS BED REST USEFUL AFTER DIAGNOSTIC LUMBAR PUNCTURE. POSTGRADUATE MEDICAL JOURNAL 1992, 68(801), 581-583.